CHF0.0015 IGPH.SW IGEA Pharma on SIX pre-market 23 Jan 2026: high volume

We see IGPH.SW stock trading at CHF 0.0015 in the SIX pre-market on 23 Jan 2026 after a sharp intraday drop of -25.00%. Volume is elevated at 2,033,000 shares versus an average of 193,941, making IGPH.SW one of the most active names on the Swiss session. This note summarizes why liquidity, microcap structure, and weak fundamentals are driving the move and where short-term traders may look for levels.

IGPH.SW stock pre-market snapshot

IGPH.SW stock opened at CHF 0.0015 on SIX with a day range CHF 0.0015–0.0020 and a previous close of CHF 0.0020. The company shows a market cap of CHF 505,545 and shares outstanding of 337,030,016. High relative volume (relVolume 10.48) signals outsized interest versus the 50-day average price of CHF 0.00214.

Business summary and recent news for IGEA Pharma N.V.

IGEA Pharma N.V. (IGPH.SW) is a Netherlands-based medical diagnostics and health-tech company. Its product set includes the Alz1 at-home blood test, supplements, COVID-19 rapid tests, and air sanitation devices. The firm lists corporate details on its site source. With one full-time employee reported, operations look very small and reliant on licensing or product sales to scale.

IGPH.SW analysis: financials and valuation

IGPH.SW shows weak fundamentals: EPS -0.03, PE -0.05, book value per share -0.00713 and a current ratio of 0.1851. Enterprise value is CHF 2,094,392.68 versus market cap CHF 505,545, reflecting leverage and low market valuation. The healthcare sector in Switzerland is up YTD +7.95%, but IGPH.SW is far smaller and underperforming sector norms.

Meyka AI rates IGPH.SW with a score of 58.55 out of 100 — Grade C+ (HOLD). This grade factors S&P 500 benchmark comparison, sector and industry performance, financial growth, key metrics, forecasts, analyst consensus and fundamental growth. These grades are informational only and not investment advice.

Trading, liquidity and technical context for IGPH.SW

As a most-active pick, IGPH.SW shows extreme intraday liquidity with volume 2,033,000 and avg volume 193,941. Price averages sit 50-day CHF 0.00214 and 200-day CHF 0.00517, indicating a long-term downtrend. Year high CHF 0.05 and year low CHF 0.0005 show large historical volatility. Short-term traders should watch support near CHF 0.0015 and resistance at CHF 0.0020.

IGPH.SW forecast and price targets

Meyka AI’s forecast model projects a short-term level around CHF 0.0020 and a 12-month scenario near CHF 0.0050, compared with the current CHF 0.0015. That implies a near-term upside of +33.33% and a 12-month upside of +233.33%, with a downside risk to CHF 0.0005 (-66.67%) if liquidity evaporates. Forecasts are model-based projections and not guarantees.

Risks and opportunities for IGPH.SW investment

Key risks include microcap illiquidity, a negative equity base, operating cash flow shortfalls, and low staff capacity. Key opportunities are niche diagnostic products, licensing upside, or a corporate tie-up. Investors should weigh the low market cap CHF 505,545, negative PE, and sector momentum before positioning. For a quick company file, see our Meyka profile source.

Final Thoughts

IGPH.SW stock trades as a microcap with active pre-market volume and wide short-term swings. At CHF 0.0015, the share reflects deep discounting versus historical highs and carries large liquidity and execution risk. Our view frames IGPH.SW as a speculative hold for traders who can absorb rapid moves. Meyka AI’s forecast model projects a near-term level of CHF 0.0020 (implied +33.33%) and a 12-month scenario near CHF 0.0050 (implied +233.33%), while noting a downside to CHF 0.0005 (implied -66.67%). These numbers are model-based projections and not guarantees. Investors should combine this with due diligence on corporate updates, product traction, and cash runway before trading on SIX in CHF.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.